D-Pharm considers plugging gap with Thrombotech buy
This article was originally published in Scrip
Executive Summary
D-Pharm has confirmed that it is in talks to acquire fellow Israeli firm Thrombotech. D-Pharm is keen to fill quickly the gap left by the failure of its lead product candidate DP-b99, which was in pivotal Phase III trials as a treatment for acute ischaemic stroke until January this year when an advisory committee concluded that it had little chance of success.